Trastuzumab biosimilar - ZydusAlternative Names: Vivitra
Latest Information Update: 02 Mar 2016
At a glance
- Originator Zydus Cadila
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed Breast cancer
Most Recent Events
- 15 Mar 2016 Biomarkers information updated
- 10 Feb 2016 Launched for Breast cancer (Metastatic disease) in India (IV)